[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL157009A0 - N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad - Google Patents

N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Info

Publication number
IL157009A0
IL157009A0 IL15700902A IL15700902A IL157009A0 IL 157009 A0 IL157009 A0 IL 157009A0 IL 15700902 A IL15700902 A IL 15700902A IL 15700902 A IL15700902 A IL 15700902A IL 157009 A0 IL157009 A0 IL 157009A0
Authority
IL
Israel
Prior art keywords
phenpropylcyclopentyl
fsad
nep inhibitors
substituted glutaramide
glutaramide derivatives
Prior art date
Application number
IL15700902A
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0107750A external-priority patent/GB0107750D0/en
Priority claimed from GB0113112A external-priority patent/GB0113112D0/en
Priority claimed from GB0120152A external-priority patent/GB0120152D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of IL157009A0 publication Critical patent/IL157009A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
IL15700902A 2001-03-28 2002-03-18 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad IL157009A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0107750A GB0107750D0 (en) 2001-03-28 2001-03-28 Novel pharmaceuticals
GB0113112A GB0113112D0 (en) 2001-05-30 2001-05-30 Novel pharmaceuticals
GB0120152A GB0120152D0 (en) 2001-08-17 2001-08-17 Novel pharmaceuticals
PCT/IB2002/000807 WO2002079143A1 (en) 2001-03-28 2002-03-18 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Publications (1)

Publication Number Publication Date
IL157009A0 true IL157009A0 (en) 2004-02-08

Family

ID=27256128

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15700902A IL157009A0 (en) 2001-03-28 2002-03-18 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Country Status (34)

Country Link
EP (1) EP1373192A1 (en)
JP (1) JP4018545B2 (en)
KR (1) KR100564466B1 (en)
CN (1) CN1243723C (en)
AP (1) AP1689A (en)
AR (1) AR035795A1 (en)
BG (1) BG108130A (en)
BR (1) BR0208455A (en)
CA (1) CA2437113A1 (en)
CZ (1) CZ20032534A3 (en)
DO (1) DOP2002000364A (en)
EA (1) EA006154B1 (en)
EE (1) EE200300469A (en)
GE (1) GEP20063783B (en)
HK (1) HK1060724A1 (en)
HR (1) HRP20030751A2 (en)
HU (1) HUP0303624A3 (en)
IL (1) IL157009A0 (en)
IS (1) IS6877A (en)
MA (1) MA26996A1 (en)
MX (1) MXPA03006597A (en)
MY (1) MY134081A (en)
NO (1) NO20034299L (en)
NZ (1) NZ527012A (en)
OA (1) OA12553A (en)
PA (1) PA8542401A1 (en)
PE (1) PE20021014A1 (en)
PL (1) PL365101A1 (en)
RS (1) RS75303A (en)
SK (1) SK11822003A3 (en)
TN (1) TNSN02032A1 (en)
TW (1) TWI254038B (en)
UY (1) UY27227A1 (en)
WO (1) WO2002079143A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
JP2005512995A (en) * 2001-11-09 2005-05-12 ファイザー ヘルス アーベー Antimuscarinic and estrogen agonists for treating unstable or overactive bladder
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0230025D0 (en) * 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
GB0230036D0 (en) * 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
PA8597401A1 (en) * 2003-03-14 2005-05-24 Pfizer ACID DERIVATIVES 3- (1- [3- (1,3-BENZOTIAZOL-6-IL) PROPILCARBAMOIL] CICLOALQUIL) PROPANOIC AS NEP INHIBITORS
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
PL1750766T3 (en) 2004-05-11 2013-12-31 Eb Ip Lybrido B V Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006027680A1 (en) * 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
JP2009503020A (en) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of flibanserin in the treatment of obesity
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
JP2009541443A (en) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Flibanserin for the treatment of urinary incontinence and related diseases
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
BRPI0716436B8 (en) 2006-08-25 2021-05-25 Boehringer Ingelheim Int controlled release system and method for manufacturing it
JP2010508358A (en) * 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー Glucocorticoid receptor, AP-1 and / or modulator of NF-κB activity, and use thereof
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
CL2008002693A1 (en) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
UY36705A (en) 2015-06-03 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware 4-HYDROXI-3- (HETEROARIL) PIRIDIN-2-ONA COMPOUNDS AS APJ AGONISTS
BR112019012251A2 (en) 2016-12-14 2019-11-05 Respira Therapeutics Inc methods and compositions for treating pulmonary hypertension and other pulmonary disorders
CN107746400A (en) * 2017-12-04 2018-03-02 武汉药明康德新药开发有限公司 The preparation method of the sulfonic acid chloride of benzodihydropyran 6
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN110483403A (en) * 2019-09-02 2019-11-22 南通大学 A kind of synthetic method of the bromo- 4- methoxyl group -1H- indazole of 5-

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2069112A1 (en) 1989-11-21 1991-05-22 Bernard R. Neustadt Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
GB9000725D0 (en) 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
GB9004260D0 (en) 1990-02-26 1990-04-18 Pfizer Ltd Therapeutic agents
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
IL139454A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

Also Published As

Publication number Publication date
BR0208455A (en) 2004-03-02
HRP20030751A2 (en) 2005-08-31
AP2002002467A0 (en) 2002-06-30
SK11822003A3 (en) 2004-09-08
EA200300777A1 (en) 2003-12-25
CZ20032534A3 (en) 2004-07-14
NZ527012A (en) 2005-03-24
IS6877A (en) 2003-07-17
BG108130A (en) 2004-07-30
KR20030092032A (en) 2003-12-03
PA8542401A1 (en) 2002-10-28
RS75303A (en) 2006-12-15
EP1373192A1 (en) 2004-01-02
EA006154B1 (en) 2005-10-27
WO2002079143A1 (en) 2002-10-10
EE200300469A (en) 2004-02-16
UY27227A1 (en) 2002-10-31
OA12553A (en) 2006-06-07
MXPA03006597A (en) 2004-10-15
NO20034299D0 (en) 2003-09-26
KR100564466B1 (en) 2006-03-29
HUP0303624A3 (en) 2005-06-28
JP4018545B2 (en) 2007-12-05
HK1060724A1 (en) 2004-08-20
PL365101A1 (en) 2004-12-27
GEP20063783B (en) 2006-04-10
NO20034299L (en) 2003-11-27
MY134081A (en) 2007-11-30
TNSN02032A1 (en) 2005-12-23
MA26996A1 (en) 2004-12-20
CA2437113A1 (en) 2002-10-10
PE20021014A1 (en) 2002-11-12
AR035795A1 (en) 2004-07-14
CN1243723C (en) 2006-03-01
HUP0303624A2 (en) 2004-03-01
CN1492852A (en) 2004-04-28
AP1689A (en) 2006-12-07
TWI254038B (en) 2006-05-01
DOP2002000364A (en) 2002-10-15
JP2004531505A (en) 2004-10-14

Similar Documents

Publication Publication Date Title
AP2002002467A0 (en) N-phenpropylcyclopen-tyl-substituted glutaramide derivatives as nep inhibitors for fsad
EG25482A (en) Inhibitors
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
HK1071360A1 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
HK1083443A1 (en) Thiazolidin-4-ones for inhibiting hyak3 proteins
SI1686119T1 (en) Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
DE60329282D1 (en) Cyano-pyrrolidines as DPP-IV inhibitors
AU2003293356A8 (en) Dihydropyridinone derivatives as hne inhibitors
EP1532133A4 (en) Nf-:b inhibitors
IL163959A0 (en) Small molecule entry inhibitors
EP1506778A4 (en) TGF-a EXPRESSION INHIBITORS
EP1547034A4 (en) Timing
EG24415A (en) Quinoline derivatives
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB0305916D0 (en) New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
AU2003243397A8 (en) Homo-camptothecin derivatives
GB0207491D0 (en) Inhibitors
GB0226149D0 (en) Inhibitors
GB0224102D0 (en) Inhibitors
GB0207488D0 (en) Inhibitors
GB0206031D0 (en) Inhibitors
GB0217330D0 (en) Inhibitors